3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
11
Phase 1
11
Phase 3
9
Phase NA
4
Phase 1/2
4
Phase 4
1
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
4
Breast
3
Other hematologic neoplasm
2
Myeloid
2
Thoracic
1
Other solid neoplasm
1
NET
1
Gynecologic
1
Genitourinary
1
Endocrine
1
Conditions
Prostatic Neoplasms
1
Interventions
Gemcitabine
9
Docetaxel
8
Androgen Antagonists
7
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
6
Magnetic Resonance Spectroscopy
6
gallium 68 PSMA-11
5
Prednisone
5
Leuprolide
5
Goserelin
5
Cisplatin
5
enzalutamide
4
bicalutamide
4
Triptorelin Pamoate
4
Radiosurgery
4
Carboplatin
4
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
4
luprolide acetate gel depot
3
Flutamide
3
Celecoxib
3
valrubicin
2
pembrolizumab
2
nilutamide
2
cabazitaxel
2
abiraterone
2
Zoledronic Acid
2
Vinblastine
2
Specimen Handling
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy
2
Nivolumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Injections
×
Genitourinary
×
Clear all
NCT06282588
2026-03-19
THUNDER
Cancer Research Antwerp
Phase 2/3
Recruiting
493 enrolled